Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
|Poll|May 20, 2019
Mini Quiz: Schizophrenia Research
Author(s)Brian Miller, MD, PhD, MPH
Current trials are investigating adjunctive monoclonal antibody immunotherapy in schizophrenia. Take the quiz and learn more.
Advertisement
Current trials are investigating adjunctive monoclonal antibody immunotherapy in schizophrenia with all of the following agents EXCEPT:
Advertisement
Related to this article
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5